ANSTO: New Joint Venture to manufacture GMP theranostic radiopharmaceuticals in Australia

The Michael Tynan Challenge is happy to welcome ANSTO to its list of beneficiaries in 2021 for their amazing contributions to scientific advancements in Health through their world-class research centres.

Cyclotek and ANSTO have announced the launch of a Joint Venture (JV), to establish Australia’s first GMP (Good Manufacturing Practice) theranostics facility starting in Melbourne, Australia.

The two leading nuclear medicine enterprises have come together to develop, manufacture and supply the next generation of therapeutic radiopharmaceuticals for cancer treatments.

The new company Applied Molecular Therapies Pty Ltd (AMT) will aim to establish a Therapeutic Goods Administration (TGA) approved, GMP manufacturing capability for a range of radiopharmaceutical therapies, initially focused on use of the radionuclide Lutetium-177.

You can read more about the joint venture and its science from the ANSTO website here.